🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
252.73
-3.23 (-1.26%)
Nov 20, 2026, 4:00 PM EST - Market closed

Ascendis Pharma Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $315.26. The average 1-year stock price forecast is 24.74% higher than the current stock price, while the lowest is $272.13 (+7.68%) and the highest is $354.32 (+40.20%).

Price Target: $315.26 (+24.74%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$272.13$315.26$313.51$354.32
Change+7.68%+24.74%+24.05%+40.20%

Analyst Ratings

The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy141416151515
Buy444555
Hold000011
Sell000000
Strong Sell000000
Total181820202121

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Citi
Citi
Buy
Maintains
$330 → $335
BuyMaintains$330 → $335+32.55%Nov 16, 2026
Barclays
Barclays
Buy
Maintains
$329 → $341
BuyMaintains$329 → $341+34.93%Nov 16, 2026
RBC Capital
RBC Capital
Buy
Maintains
$290
BuyMaintains$290+14.75%Nov 13, 2026
Leerink Partners
Leerink Partners
Buy
Reiterates
$326
BuyReiterates$326+28.99%Nov 13, 2026
Bank of America Securities
Bank of America Securities
Buy
Reiterates
$304
BuyReiterates$304+20.29%Nov 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.38B
from 720.13M
Increased by 91.55%
Revenue Next Year
2.02B
from 1.38B
Increased by 46.52%
EPS This Year
15.98
EPS Next Year
10.78
from 15.98
Decreased by -32.55%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Jan 1, 2023Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
7.78M51.17M266.72M363.64M720.13M1.38B
Revenue Growth
11.87%557.93%421.20%36.34%98.03%91.55%
Gross Profit
4.26M39.04M222.32M319.38M625.22M1.27B
Gross Margin
54.71%76.28%83.36%87.83%86.82%92.03%
Operating Income
-451.79M-561.81M-455.54M-278.76M-136.27M481.43M
Net Income
-383.58M-583.19M-481.45M-378.08M-228.03M1.02B
EPS
-----15.98
Forward PE
-----14.42
Free Cash Flow
----45.41M674.38M
No. Analysts
-----17
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue202620272028
High1.5B
Avg1.4B
Low1.4B

Revenue Growth

Revenue Growth202620272028
High
109.6%
Avg
91.6%
Low
88.2%

EPS Forecast

EPS202620272028
High18.15
Avg15.98
Low14.97

EPS Growth

EPS Growth20272028
High
4.3%
Avg
-32.6%
Low
-47.2%